Table 3.

Outcome measures with matching cohorts considering only patients with normal renal function at ICU admission

OutcomeMidazolam-Matched
Cohort (n=346)Propofol-Matched
Cohort (n=354)P
ValueOR
(95%CI)
AKI stage 160 (17.3)62 (17.5)1.01 (0.69 to 1.48)
AKI stage 287 (25.1)66 (18.6)<0.0010.68 (0.48 to 0.98)
AKI stage 359 (17.1)30 (8.5)0.45 (0.28 to 0.72)
Oliguria (<400 ml/d)a42/319 (13.2)14/334 (4.2)<0.0010.29 (0.15 to 0.54)
Diuretic use43 (12.4)25 (7.1)0.010.54 (0.33 to 0.89)
Cumulative fluid balance >5% body wt195 (56.3)173 (48.9)0.010.81 (0.69 to 0.95)
RRT6 (1.7)2 (0.6)0.130.32 (0.06 to 1.61)
ICU mortality69 (19.9)32 (9.0)<0.0010.40 (0.25 to 0.63)
  • Except for ICU mortality, all outcomes were considered for the first 7 days of ICU stay. ICU, intensive care unit; OR, odds ratio; 95% CI, 95% confidence interval.

  • a Urine output was accessible in 653 patients (93.3%).